MedAdvisor Stock

MedAdvisor Equity

The The Equity of MedAdvisor (MDR.AX) as of Jun 22, 2026 is 1.05 T AUD.In the previous year, The Equity was 51.58 T AUD — a change of -97.97% (lower).

Equity

1.05 TAUD

YoY

-97.97%

Last updated:

In 2026, MedAdvisor's equity was 1.05 T AUD, a -97.97% increase from the 51.58 T AUD equity in the previous year.

Access this data via the Eulerpool API

MedAdvisor Stock analysis

What does MedAdvisor do? Medadvisor Ltd is an Australian company that offers a digital platform for healthcare. Founded in 2012 by Robert Read, David Liu, and Josh Swinnerton, their aim was to develop a platform that simplifies medication management for patients, pharmacies, and doctors. Today, Medadvisor is a publicly traded company with a wide range of digital healthcare solutions. They offer various solutions to support patients in medication intake and management, such as a mobile application that allows patients to manage their medications, order prescriptions, and receive reminders. They also offer solutions for pharmacies, including an online ordering system and access to electronic patient history, as well as a platform for doctors to electronically issue prescriptions. One of their latest products is a mobile application that facilitates the handling of COVID-19, providing real-time virus spread tracking and symptom tracking tools. Medadvisor focuses on meeting customer needs and continuously improving the healthcare process. They recently partnered with Take2 Healthcare to expand their range of solutions and create the best offering of health solutions. Overall, Medadvisor plays an important role in the Australian healthcare system by helping their customers live happier and healthier lives through innovative technologies and services. MedAdvisor is one of the most popular companies on Eulerpool.

Equity Details

Analyzing MedAdvisor's Equity

MedAdvisor's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding MedAdvisor's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating MedAdvisor's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

MedAdvisor's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in MedAdvisor’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about MedAdvisor stock

The Equity of MedAdvisor amounted to 51.58 T AUD 1.05 T

Access this data via the Eulerpool API

Balance Sheet — MedAdvisor

All Key Metrics — MedAdvisor